Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Other Non-Current Liabilities (2016 - 2020)

Historic Other Non-Current Liabilities for International Stem Cell (ISCO) over the last 11 years, with Q3 2020 value amounting to $40000.0.

  • International Stem Cell's Other Non-Current Liabilities changed N/A to $40000.0 in Q3 2020 from the same period last year, while for Sep 2020 it was $40000.0, marking a year-over-year change of. This contributed to the annual value of $207000.0 for FY2019, which is 8813.75% down from last year.
  • Per International Stem Cell's latest filing, its Other Non-Current Liabilities stood at $40000.0 for Q3 2020.
  • In the past 5 years, International Stem Cell's Other Non-Current Liabilities registered a high of $19.6 million during Q1 2016, and its lowest value of $40000.0 during Q3 2020.
  • In the last 5 years, International Stem Cell's Other Non-Current Liabilities had a median value of $2.3 million in 2016 and averaged $3.3 million.
  • As far as peak fluctuations go, International Stem Cell's Other Non-Current Liabilities surged by 75564.85% in 2016, and later plummeted by 9155.05% in 2020.
  • Quarter analysis of 5 years shows International Stem Cell's Other Non-Current Liabilities stood at $2.0 million in 2016, then skyrocketed by 52.22% to $3.1 million in 2017, then crashed by 43.94% to $1.7 million in 2018, then tumbled by 88.14% to $207000.0 in 2019, then crashed by 80.68% to $40000.0 in 2020.
  • Its Other Non-Current Liabilities stands at $40000.0 for Q3 2020, versus $322000.0 for Q2 2020 and $97000.0 for Q1 2020.